BetterLife Pharma Expands Leadership with New Appointment
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CNSX: BETR.CN / OTCQB: BETRF / FRA: NPAU), an up-and-coming biotechnology enterprise, proudly announces the appointment of André Beaudry as its new Corporate Advisor. With over 30 years of invaluable experience in fundraising, government relations, and program management across various sectors, Mr. Beaudry is set to enhance BetterLife's strategic efforts.
His leadership roles have taken him across several countries, including Canada, China, England, India, and the Philippines. Mr. Beaudry has been instrumental in collaborating with industry leaders and governmental institutions to raise over $140 million for numerous projects, with a significant focus on mental health initiatives. In his role as the Founder of Velocity Collaboration Corporation, he continually aims to unlock the potential of organizations through strategic advisory capabilities.
Insightful Visions for BetterLife's Future
“I’m a proud supporter and shareholder of BetterLife. Over the years, I have come to respect the scientists and scholars connected to this organization,” commented Mr. Beaudry. He praised the company’s significant progress, highlighting how they have developed and tested their innovative non-hallucinogenic compound, BETR-001. This compound has shown promise in renewing brain neural circuits affected by chronic stress or trauma.
Looking ahead, Mr. Beaudry expressed enthusiasm about collaborating with BetterLife's management and board. He is driven by the goal of propelling BETR-001 into human clinical trials to help millions lead healthier lives. With the successful completion of most of its FDA-required IND-enabling studies, Mr. Beaudry believes that BetterLife is on the verge of unveiling the true potential of BETR-001 as a safe and accessible therapeutic solution for prevalent issues such as anxiety, depression, PTSD, addiction, and chronic migraines.
The Visionary Leadership of Ahmad Doroudian
Ahmad Doroudian, CEO of BetterLife, welcomed André Beaudry, emphasizing the immense value his vast fundraising expertise brings to the company's plans. “We are excited to have André join the BetterLife team. His rich background in various fundraising realms will significantly aid us in our quest to launch a patient-friendly, non-hallucinogenic medicinal option to address numerous psychiatric and neurological conditions,” he stated.
About BetterLife Pharma and Its Pioneering Compounds
BetterLife Pharma Inc. is focused on the development and commercialization of groundbreaking compounds like BETR-001 and BETR-002, targeting neuro-psychiatric and neurological disorders. BETR-001 is undergoing preclinical and IND-enabling studies and is a unique non-hallucinogenic LSD derivative that can be self-administered due to its unregulated status. The synthesis patent for BETR-001 minimizes regulatory challenges, while its pending patent protects its use in treating major depressive disorder and anxiety disorder among others.
Similarly, BETR-002, also in preclinical and IND-enabling studies, utilizes honokiol, a natural anxiolytic derived from magnolia bark. This compound is engineered to effectively treat anxiety-related disorders, including dependency on benzodiazepines. Additionally, BetterLife is advancing a drug candidate intended for viral infections and is actively pursuing strategic options for its further development.
For additional details, please visit BetterLife Pharma.
Frequently Asked Questions
What is BetterLife Pharma known for?
BetterLife Pharma specializes in developing and commercializing innovative compounds aimed at treating neuro-psychiatric and neurological disorders.
Who has BetterLife Pharma appointed as the Corporate Advisor?
André Beaudry has been appointed as the Corporate Advisor, bringing extensive experience in fundraising and program management.
What are the key compounds BetterLife Pharma is developing?
The key compounds include BETR-001, a non-hallucinogenic compound in clinical development, and BETR-002, which is based on honokiol for anxiety-related disorders.
Why is BETR-001 significant?
BETR-001 is significant for its potential to renew brain neural circuits impacted by chronic stress or trauma and its unique self-administration capability due to its unregulated nature.
How can I contact BetterLife Pharma for more information?
You can reach out to David Melles, Investor Relations Manager, at David.Melles@blifepharma.com or call 1-778-887-1928 for inquiries.
